key: cord-0822461-t84fl73r
authors: Pham, Thang L.; He, Jiucheng; Kakazu, Azucena H.; Calandria, Jorgelina; Do, Khanh V.; Nshimiyimana, Robert; Lam, Ting F.; Petasis, Nicos A.; Bazan, Haydee E. P.; Bazan, Nicolas G.
title: ELV-N32 and RvD6 isomer decrease pro-inflammatory cytokines, senescence programming, ACE2 and SARS-CoV-2-spike protein RBD binding in injured cornea
date: 2021-06-17
journal: Sci Rep
DOI: 10.1038/s41598-021-92293-x
sha: 6f9998221f74bbdbb52e3030fdbe87178348b209
doc_id: 822461
cord_uid: t84fl73r

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection that causes coronavirus disease 2019 (COVID-19) has resulted in a pandemic affecting the most vulnerable in society, triggering a public health crisis and economic collapse around the world. Effective treatments to mitigate this viral infection are needed. Since the eye is a route of virus entrance, we use an in vivo rat model of corneal inflammation as well as human corneal epithelial cells (HCEC) in culture challenged with IFNγ as models of the eye surface to study this issue. We explore ways to block the receptor-binding domain (RBD) of SARS-CoV-2 Spike (S) protein to angiotensin-converting enzyme 2 (ACE2). We found that the lipid mediators, elovanoid (ELV)-N32 or Resolvin D6-isomer (RvD6i) decreased the expression of the ACE2 receptor, furin, and integrins in damaged corneas or IFNγ-stimulated HCEC. There was also a concomitant decrease in the binding of Spike RBD with the lipid treatments. Using RNA-seq analysis, we uncovered that the lipid mediators also attenuated the expression of pro-inflammatoy cytokines participating in hyper-inflammation and senescence programming. Thus, the bioactivity of these lipid mediators will contribute to open therapeutic avenues to counteract virus attachment and entrance to the body.

after injury with and without treatment (Fig. 1b) revealed well-clustered transcriptional profiles in each treated group (Fig. 2a) . In principal component analysis (PCA) plots (Fig. 2a) , the transcriptomic profile of non-injured corneas, control (red), and injured corneas treated with vehicle (green) were separated well. Topical treatment with lipid mediators shows profiles closer to control corneas than to vehicle-treated corneas. ELV-N32 (pink) was the nearest to the normal cornea, follow by RvD6i, LXA4, and NPD1. DEseq2 analysis allows comparison of all treated groups as well as control corneas to vehicle as a reference. Upregulated genes in vehicle-treated injury corneas revealed differences among treatment with lipid mediators, as depicted in Venn diagrams (Fig. 2b) . Since NPD1 failed to decrease the ACE2 expression and RBD binding upon injury (Fig. 1d-h) , we focused on the groups of shared genes (red circles) between control-LXA4-ELV-N32-RvD6i (450 genes including Ace2) and control-ELV-N32-RvD6i (737 genes). The EnrichR generating-KEGG pathway analysis of these two data sets revealed cytokines and senescence-related pathways (Fig. 2c ) with significant false discover rate (FDR) values. On the other hand, IPA analysis of these two gene set combinations (1187 genes in total in Fig. 2b ) predicted several cytokines as upstream regulators of increased Ace2 expression after injury (Fig. 2d ). In addition to cytokines, the senescence maker CDKN2A (p16/INK4) and the NFkB (complex) and its correlated genes were predicted to be inducers of Ace2 (Fig. 2d) . The RNA-seq analysis of the Cdkn2a gene (Fig. 2e) , the IPA inhibition score and Figure 1 . Selective lipid mediators reduce cornea injury-induced expression of ACE2 and binding of Alexa 594-RBD. (a) Expression of Ace2, Dpp4, furin and Tmprss2 in the uninjured rat cornea. Left: representative immunofluorescence imaging. DAPI stains nuclei (blue). Immunofluorescence shows ACE2 expressed in the epithelium and stroma. Right: RNA-seq data. (b) Experimental design. After alkali burn, rats received eye drops of lipid mediators or vehicle 20 μL/eye, 3 times/day for 14 days (double-blinded). ACE2 expression was assayed at day 14 after injury ± lipids treatment. At day 15, rats were treated with Alexa 594-RBD (1 µg/eye, 3 times) and corneas examined a day later. (c) Lipid mediators studied. The chirality in all figures of RvD6i and NPD1 used in this study had the R,R stereochemistry. (d) ACE2 abundance before and after injury ± lipids using Jess capillarybased Western Blot system (Protein Simple). ACE2 densitometry normalized to GAPDH in the same capillary to minimize errors. Data is from one rat cornea for each data point (N = 4). The p-values of ANOVA-post hoc Dunnett's multiple comparisons test with vehicle as reference are shown. Mean and SD are depicted as the lines. (e) Illustration showing corneal analysis by wholemount (x and z planes-orange color) and cross-section (x and y planes-blue color). (f) Wholemount images of binding of Alexa 594-RBD in corneas after injury and treatments. The control cornea (no-injury) has very low Alexa 594-RBD signal, while the injured cornea shows intense fluorescence. LXA4, ELV-N32, and RvD6i decrease Alexa 594-RBD binding while NPD1 fails. (g) Crosssection images of the same corneas shown in (f). The green lines were added to separate the epithelium from the stroma. Most of Alexa 594-RBD signal was found in the stroma. (h) Quantification of Alexa 594-RBD positive cells. Each data point represents number of cells/cross-section image. Values are means ± SD and p-values calculated by ANOVA-post hoc Dunnett's multiple comparisons test with vehicle as reference (4 images/cornea and 4 rat corneas/condition). The map of image capture is shown in Supplementary Fig. S2 Lipid mediators counter-regulate pro-inflammatory cytokines, NFkB/inflammation, and senescence-associated secretory phenotype after cornea injury. Since upregulated Ace2 gene expression is caused by the action of cytokines, p16INK4a, and NFkB, we targeted genes regulated by these inducers. Thus, in the injured cornea, we explored: (i) activated cytokines found in the serum of SARS-CoV-2 patients 22 , (ii) senescence-associated secretory phenotype (SASP) genes 25 , and (iii) NFkB/inflammation genes found in lung biopsies of SARS-CoV-2 26 . The Venn diagram showed several genes shared by the three inducers (Fig. 3a) . The Heatmap indicated that 51 injury-upregulated genes were counteracted by the lipid mediators (Fig. 3b ). All 51 of these genes belong to the cytokines and SASP-related genes ( Supplementary Fig. S3a ). The plot for each specific gene is provided in Supplementary Figs Fig. S4 ), Mmp3, Mmp12, and Timp1 ( Supplementary Fig. S5 ), are increased after coronavirus infection and involved in the degradation of the extracellular matrix, which facilitates hyper-inflammation, leukocyte infiltration, and ECM remodeling and fibrosis 28, 29 . Further, transient receptor Trpc6 ( Supplementary Fig. S4 ) is a component of chronic obstructive pulmonary disease development 30 .

Using pathway analysis, we found similar pathways to those found in the entire transcriptome ( Fig. 2c and Supplementary Fig. S3a ). Employing the EnrichR-Archs4 human analysis tissue database, we found that the 51 genes are more abundant in the omentum and lung (bulk tissue) (Fig. 3c ). This suggests that genes detected in the injured cornea might recapitulate changes in gene expression that occur after lung injury. Three targeted cytokines, Il1b, Il6, and Vegfa genes, are plotted in Fig. 3d . Our data showed that these genes were upregulated by the injury, and the administration of LXA4, ELV-N32, or RvD6i reduced their expression. We also focused on integrin genes since the Spike protein contains an arginine-glycine-aspartic acid motif in the RBD site that is recognized by some integrins as a potential receptor of SARS-CoV-2 31, 32 . Six integrins, which have the RGD binding domain in the heterodimer conformation, are increased after injury and decreased by some of the lipid mediators (Fig. 3e ). Among these genes, Itga5 and Itgb1 are of interest since their specific blocker ATN-161 greatly attenuates the SARS-CoV-2 infection in vitro 33 , and their expression is significantly decreased by ELV-N32 and RvD6i.

Lipid mediators attenuate IFNγ-specific induction of ACE2 expression, RBD exposure, and senescence programming in HCEC. Based on the IPA prediction that upstream regulators of Ace2 targeted some cytokines, we treated HCEC with IL1β, IL2, IL6, IL8, IFNγ, IFNα, IFNε, or TNFα at 1, 10, and 100 ng/ mL concentrations. IFNγ and IFNα were the only cytokines to activate Ace2 expression, with IFNγ being the more potent of the two, inducing ACE2 expression at 1 ng/mL. Therefore, we chose IFNγ as the inducer of Ace2 in the HCEC experiment ( Fig. 4a and Supplementary Fig. S6 ). Following Ace2 expression by dd-PCR that provides absolute quantification at the transcription level, ELV-N32 and RvD6i markedly attenuated IFNγ-triggered Ace2 activation while LXA4 did not have any effect. (Fig. 4b ). In addition, IFNγ stimulates the overexpression of senescence programming genes Cdkn2a (p16INK4a) and Mmp1. ELV-N32, RvD6i, and NPD1 decrease Cdkn2a activation to control values, but LXA4 does not. IFNγ-stimulated Alexa 594-RBD binding was analyzed by Imaris ( Fig. 4c and Supplementary Fig. S7 ) correlates with increased ACE2 expression (Fig. 4b) . ELV-N32, RvD6, and NPD1 decrease IFNγ-stimulated RBD binding (Fig. 4c) . Following IFNγ-stimulated RBD binding to ACE2, induction of senescence programming genes Cdkn2a (p16INK4a) and Mmp1, and SASP secretome activation (β-Gal staining) takes place. These events are blocked by ELV-N32, RvD6i, and NPD1 but not by LXA4 (Fig. 4d ).

Selective lipid mediators disrupt ACE2 upregulation and injury-mediated hyper-inflammation, senescence, and pro-inflammatory cytokines components. (a) PCA plot of RNA-seq data. Rat corneas were analyzed at day 14 after injury ± treatments (Fig. 1b) . Each data point represents one animal (N = 5/group, except LXA4 with N = 3 and control with N = 6). The eclipse of 95% confidence interval was used to group data points from the same set of treatment. (b) Venn diagram of significant genes (FDR < 0.05) upregulated by the vehicle treatment of injured corneas (RNA-seq data set was analyzed using DEseq2 with vehicle injured corneas as reference). The negative log2 fold change genes (upregulated by vehicle) with FDR < 0.05 were used. We excluded NPD1 because it failed to decrease Ace2 expression upon injury (Fig. 1d ). The groups of shared genes between control-LXA4-ELV-N32-RvD6i and control-ELV-N32-RvD6i are depicted in red circles. (c) The KEGG-pathway enrichment networks obtained from EnrichR tool of selected genes from (b). Bars were sorted by p-value. The length of the bar represents the significance of the pathway, while the lighter the color, the higher the significance. The number shows amount of genes from denoted group that are enriched in each pathway. (d) IPA upstream regulator analysis of significant genes vs. vehicle (injury) group. There are proteins with negative activation z-score compared to vehicle group (blue color). Among those are CDKN2A and NFkB (complex). (e) RNA-seq normalized counts of Cdkn2a gene that encodes the senescence key-marker p16INK4a; ELV-N32 decrease its expression. Data correspond to one cornea for each data point and is presented as mean ± SD. The p-values were analyzed by ANOVA-post hoc Dunnett's multiple comparisons test with vehicle as reference. The normalized counts were used for analysis. IPA scores for CDKN2A (f) and NFkB (complex) (g) upstream regulators. The left y-axis is the inhibition z-score, while the right y-axis e is − log10 of p-value. The cutoff line for p-value is < 0.05. The protein level of IL1B and VEGF were confirmed using Jess capillary-based western assay ( Supplementary Fig. S8 ). 

The severe COVID-19 outbreak is characterized by hyper-inflammation and "cytokine storm, " therefore, the management of local and systemic inflammatory response to SARS-CoV-2 may be as important as antiviral therapies. Among anti-inflammatory agents, the specialized pro-resolvin lipid mediators (SPMs), such as LXA4, NPD1 and RvD6i, facilitate the clearance of cell debris and counteract the action of pro-inflammatory cytokines in a process called "inflammation resolution without any immunosuppressive complications" 34 . Recently, SPMs were hypothesized as potential COVID-19 treatments 9-11 . However, practical evidence, as well as working mechanisms, were not available. Here, we discern bioactivity among a group of lipid mediators on ACE2 expression, pro-inflammatory cytokines, and senescent proteins, which are critical targets related to SARS-CoV-2 entrance and deleterious consequences of this viral infection. We uncover that the lipid mediators ELV-N32 and RvD6i decrease ACE2 receptor expression and binding of RBD of the S protein, preventing enhancement of cytokine expression and senescence programming using a rat cornea in vivo model of alkali burn that induces a strong inflammatory reaction. Using HCEC in culture challenged with IFNγ, we found that ELV-N32 and RvD6i exert similar effects. In addition, ELV-N32 remarkably decreases Furin expression, a protease that cleaves the S1/S2 site required for SARS-CoV-2 entry in lung cells 6 .

A key cytokine responding to viral infections is IFNγ 35 , which increases in the serum of severely affected COVID-19 patients 22, 36 . We found that IFNγ induces Ace2 expression in HCEC at a much lower dose than IFNα and increases the binding of the RBD to the cells. Moreover, IFNγ activates cellular senescence reflected in enhanced Cdkn2a expression and SASP secretome release. This observation could contribute to explaining why aging populations are more susceptible to COVID-19 37 . ELV-N32 does bear senolytic activity 19 , and both ELV-N32 and RvD6i suppressed senescence genes and SASP secretome in HCEC (Fig. 4d) . Therefore, S protein internalization may lead to IFNγ secretion, which would synergize with an integrin-rich environment to amplify the IFNγ effect 38 and stimulate Ace2 overexpression. As a result, the higher the ACE2, the higher the possibility of SARS-CoV-2 binding will be. ELV-N32 and RvD6i suppressed the IFNγ stimulation of Ace2 expression as well as the IFNγ-induced senescence, where many SASP components are pro-inflammatory cytokines. PEDF + DHA (the precursor of RvD6i) and RvD1 suppress type 1 pro-inflammatory macrophages (induced by IFNγ) while increasing the type 2 anti-inflammatory macrophage phenotype 39, 40 . Interestingly, ELV-N32, RvD6i, and NPD1 attenuated the binding of ACE2-RBD in the IFNγ-treated cells in culture (Fig. 4c) , while in the rat injured cornea, LXA4 displayed a significant effect on preventing ACE2-RBD interaction (Fig. 1f-h) . Of the lipid mediators studied, ELV-N32 and RvD6i are the two most consistent lipid mediators displaying protective bioactivity. RvD6i was recently identified in mouse tears as related to corneal nerve regeneration 17, 41, 42 . ELV-N32 is a powerful neuroprotective and anti-inflammatory lipid mediator 18 .

Tissue damage is a serious complication of SARS-CoV-2-infected patients. Recently, Rosa et al. demonstrated that, in both tuberculosis and COVID-19 (two pulmonary diseases where neutrophils are associated with increased severity), there is an upregulation of neutrophil degranulation, innate immune response, ACE2 level, and IFNγ signaling pathways 43 . These results are similar to what we found in our cornea alkali-burn-damage model. Therefore, corneal alkali burn as a tissue damage model mimics the physical response of intestinal or lung epithelial cells during and after SARS-CoV-2 infection.

ACE2 is an anti-inflammatory factor 44 and is also a SARS-CoV-2 receptor 4 . Thus, the increased abundance of ACE2 in damaged tissue, such as the lung or the cornea in this study, is a double-edged sword, especially when the anti-inflammatory activity is inadequate in diminishing the pro-inflammatory cytokines produced by the infection. The lipid mediators ELV-N32 and RvD6i might be an alternative way of providing anti-inflammatory activity. Even though the action of LXA4 or NPD1 was not consistent between in vitro and in vivo models, the potential of using lipid mediators to maintain the homeostasis after tissue damage is remarkable, especially in the current scenario in which the 'long COVID' (the long-lasting health effects of SARS-CoV-2 infection) is not well-documented.

ELV-N32 and RvD6i also decrease integrin expression. The S protein contains an RGD motif in the RBD site that recognizes integrins and stimulates virus internalization by activation PI-3K 31,32 , a pathway that the KEGG analysis from EnrichR tool predicted to increase along with ACE2 enhanced expression (Fig. 2c) . The inhibition of integrin α5β1 by a non-RGD peptide derived from fibronectin prevents the binding of the S protein to ACE2 and decreases virus infection in vitro 33 .

Recently, Miner et al. showed that the human cornea does not support SARS-CoV-2 infection despite the expression of ACE2 in the human corneal epithelium 45 . However, studies in COVID-19 patients found an increase of the virus in dry eye disease, suggesting a possible consequence of infection 46 , and in a cohort of patients with COVID-19, 63% had a positive viral test in the conjunctiva, but the origin of the infection was undetermined 47 . Nevertheless, the role of lipid mediators in managing the ACE2 upregulation as well as hyper-inflammation, increase in cytokine expression, and senescence programming after tissue damage uncovers mechanistic insights that are also applicable to other tissues.

In conclusion, our data demonstrate that ELV-N32 or RvD6i diminish ACE2 expression and binding of the S protein RBD and, consequently, activate pro-homeostatic signaling and reduce tissue damage.

The application of these lipid mediators alone or as a complement with current antiviral strategies for COVID-19 could be of therapeutic use. Moreover, the lipid mediators identified here might work by similar mechanisms in other cell types and further expand the scope of their therapeutic applications.

Limitations of this study. Additional research will be needed to fully elucidate the molecular mechanisms by which the lipid mediators downregulate ACE2 and the genes encoding inflammatory/senescence proteins. The use of the full-length S protein or the pseudotype-virus that expresses SARS-CoV-2 S protein in the models studied here will provide insights into the molecular connection between lipid mediators acting on the cell To determine if the lipid have any side effects in the non-injured rat eye, eye drops at the same concentrations were used 3 ×/day for 1 week. The treatment did not produce blinking or rubbing of the eyes. There were no signs of conjunctiva hyperemia or edema using slit-lamp examination. The experiments were double-blinded with the lipid mediators coded during the whole experiments. At the end of the study, when all data was collected, the code was opened.

Antibodies. See Table 1 .

Corneal RNA-sequencing. Injured corneas (n = 5/condition) were harvested and homogenized with TRIzol (ThermoFisher Scientific) on ice with a glass Dounce homogenizer. RNA sequencing was performed as described 17 . Briefly, after mRNA extraction and determination of purity, 8 ng of total RNA was reverse transcribed, and total cDNAs were amplified using ISPCR primer, and the library was made with the Nextera XT DNA library preparation kit (Illumina, San Diego, CA, USA). The libraries were pooled with the same molarity and sequenced using the NextSeq 500/550 High Output Kit v2 (75 cycles, Illumina). After demultiplexing, RNAseq data were aligned to the Rattus Norvegicus reference genome (ftp:// ftp. ensem bl. org/ pub/ relea se-98/ fasta/ rattus_ norve gicus/ dna/) using the Subread package v2.0.1 alignment function 48 . The BAM files for sequencing data alignment were counted using featureCounts function of Subread tool 49 using the macOS Catalina. The raw count data were subjected to differential gene expression analysis using DESeq2 package for R 50 with the vehicle group as reference. The adjusted p-values were named as the false discover rate (FDR). Significantly changed genes (FDR < 0.05) between each treatment vs. vehicle were subjected to the enrichment analysis using EnrichR 51 and NetworkAnalyst 3.0 52 , and pathway analysis using the IPA (Qiagen Inc., https:// www. qiage nbioi nform atics. com/ produ cts/ ingen uity-pathw ay-analy sis).

Preparation of Alexa 594-conjugated RBD fragment of S protein. RBD For screening the stimulation of receptor ACE2 by cytokines, the HCEC were cultured with KGM until 50-60% confluence. Then, changed to KBM containing IL-1β, -2, -6 and 8, IFN-α, -ε, and -γ or TNFα at 1, 10 or 100 ng/mL. The cells were harvested after 6 h and analyze for the gene expression of Ace2. In other experiments, HCEC were stimulated with IFNγ, and thereafter, lipid mediators were added. For the Alexa 594-conjugated RBD binding, IFNγ was used as a cytokine trigger. At 12 h after cytokine exposure and lipid mediator treatments, 0.5 μg of labeled RBD was added to the medium. The evaluation of RBD binding was conducted 24 h after.

Immunohistochemistry. Corneal tissue was fixed in Zamboni fixative (MasterTech Scientific, Lodi, CA USA) for 2 h immediately after euthanasia. After thoroughly washing with PBS, the corneas were embedded in optimal cutting temperature compound, and serial 10-μm cryostat sections were obtained, dried at room temperature for 2 h, and stored at − 20 °C until use. For immunofluorescence, the sections were incubated with primary antibodies at the concentration described in Table 1 in a wet chamber at 4 °C overnight. The sections were washed 3 ×/5 min with PBS following by incubation for 1 h at RT with Alexa Fluor-conjugated secondary antibodies (1:1000 dilution). All sections were counterstained with DAPI (ThermoFisher Scientific, Cat. D1306), and images of rat corneal samples were acquired with an Olympus IX71 fluorescent microscope.

Unbiased imaging-based evaluation of RBD binding. Twenty-four hours after Alexa 594-RBD was added to the HCEC, the cells were washed with PBS (3 ×/5 min) and fixed with 4% paraformaldehyde for 30 min at RT. The HCEC were washed 2 × with PBS and stained with Hoechst 33342 Solution (ThermoFisher Scientific, Cat. 62249) for 30 min at RT. Next, the HCEC were washed 2 × with PBS before imaging. For unbiased data collection, 7 designated areas were defined in each well (Supplementary Fig. S7 ) and captured with an Olympus FV3000 confocal laser scanning microscopy under "Multi Area Time Lapse" (MATL) mode. All images were acquired with the same parameters and Z-section range, converted and inputted in the Imaris software version 9.5.1. The threshold for the control images was defined by the HCEC without Alexa 594-conjugated RBD of S protein and using it as a threshold filter for the Imaris batch image processing function. The sum of total intensity for each image was used to evaluate the binding efficiency. The whole process was summarized in Supplementary  Fig. S7b ,c.

Droplet digital PCR (dd-PCR). Total RNA was isolated using RNeasy Plus Mini Kit (Qiagen, Germany), and 1 µg of total RNA was reverse transcribed using an iScript cDNA Synthesis Kit (Bio-Rad, Cat. 170-8841). For ddPCR, 10 ng of cDNA was multiplexed with Ace2 and phosphoglycerate kinase 1 (Pgk1) probes (Bio-Rad, Cat. qHSACEP005-1563 and dHSACPE503-3809) using dd-PCR Supermix for Probes No dUTP (Bio-Rad, Cat. 1863024). Then, 20 µL of the reaction was mixed with 70 µL of Droplet Generation Oil (Bio-Rad Cat. 1863005) to make the reaction droplets. The emulsified samples were carefully transferred to PCR plates (Bio-Rad, Cat. 12001925) and amplified using the cycling: 95 °C for 10 min, 40 cycles of a two-step cycling protocol (94 °C for 30 s and 60 °C for 1 min), and 98 °C for 10 min. Next, the post-cycling plate was placed into the QX200 Droplet Reader with the FAM/HEX setting. The absolute quantity of DNA per sample (copies/µL) was processed using QuantaSoft Analysis Pro Software. For the data analysis, the ratio of quantified Ace2 to Pgk1 was used.

Capillary-based western blot. The capillary-based western assay was performed using a Jess system (Protein Simple, San Jose, CA, USA) as manufacture suggested protocol. Briefly, samples were lysed with RIPA buffer containing a protease inhibitor cocktail (Sigma, Cat. P8340). Cell debris was removed after 10 min centrifugation at 16,000×g. Protein concentration was determined by BCA assay (ThermoFisher Scientific, Cat. 23225) and www.nature.com/scientificreports/ (PN 100-5580; Fluidigm). The cDNA was then subjected to Exonuclease I treatment and diluted 5 times in TE Buffer. The qPCR reaction mixture and primer reaction mixture were made and loaded into the Biomark 96.96 IFC (Integrated Fluidic Circuit). The enzyme reaction was mixed using Juno Controller (Fluidigm) and run using the cycling program of (i) 70 °C for 40 min followed by 60 °C for 30 s, (ii) hot start for 1 min at 95 °C, (iii) 30 cycles of denaturation at 96 °C for 5 s, and annealing at 60 °C for 20 s, and (iv) melting curves between 60 °C and 95 °C with 1 °C increments/3 s. The Ct value of target genes was normalized to the house-keeping genes Gapdh, Hprt1, and Tfrc before normalized to the vehicle group. Relative fold changes from the ΔΔC T calculation was used to make the graph. Primer sequences are provided in Table 2 .

Statistical analysis. Data are expressed as mean ± SD. The data were analyzed by 1-way ANOVA followed by Dunnett's multiple comparisons post hoc test at 95% confidence level with the vehicle as reference. All graphs were made using GraphPad Prism 7 (GraphPad Software, La Jolla, CA, USA) with the mean ± SD, while all statistical analyses were done using the built-in function of Prism 7.

The data that support the findings of this study are available from the corresponding authors upon reasonable request. 

Naming the coronavirus disease (COVID-19) and the virus that causes it

A novel coronavirus from patients with pneumonia in China

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

The MERS-CoV receptor DPP4 as a candidate binding target of the SARS-CoV-2 spike

A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells

SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes

ACE2 and TMPRSS2 are expressed on the human ocular surface, suggesting susceptibility to SARS-CoV-2 infection

Inflammation resolution: A dual-pronged approach to averting cytokine storms in COVID-19

Covid-19 management with inflammation resolving mediators? Perspectives and potential

Can bioactive lipids inactivate coronavirus (COVID-19)?

Response to: Bioactive lipids and coronavirus (COVID-19)-further discussion

Pro-resolving lipid mediators are leads for resolution physiology

Lipoxins: Novel series of biologically active compounds formed from arachidonic acid in human leukocytes

Docosanoids and elovanoids from omega-3 fatty acids are pro-homeostatic modulators of inflammatory responses, cell damage and neuroprotection

Neuroprotectin D1: A docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress

Novel RvD6 stereoisomer induces corneal nerve regeneration and wound healing post-injury by modulating trigeminal transcriptomic signature

Elovanoids are novel cell-specific lipid mediators necessary for neuroprotective signaling for photoreceptor cell integrity

Elovanoids counteract oligomeric β-amyloid-induced gene expression and protect photoreceptors

SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues

Characteristics of ocular findings of patients with coronavirus disease 2019 (COVID-19

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

SARS-CoV-2: A storm is raging

Cytokine expression in the alkali-burned cornea

The senescence-associated secretory phenotype: The dark side of tumor suppression

SARS-CoV2-mediated suppression of NRF2-signaling reveals potent antiviral and anti-inflammatory activity of 4-octyl-itaconate and dimethyl fumarate

Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19

The role of metalloproteinases in corona virus infection

Distinct and early increase in circulating MMP-9 in COVID-19 patients with respiratory failure

Role of oxidative stress and transient receptor potential in chronic obstructive pulmonary disease

A potential inhibitory role for integrin in the receptor targeting of SARS-CoV-2

A potential role for integrins in host cell entry by SARS-CoV-2

The integrin binding peptide, ATN-161, as a novel therapy for SARS-CoV-2 infection

The resolution code of acute inflammation: Novel pro-resolving lipid mediators in resolution

Antiviral actions of interferons

Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors

COVID-19)

Paracrine costimulation of IFN-γ signaling by integrins modulates CD8 T cell differentiation

Resolvin D1 polarizes primary human macrophages toward a proresolution phenotype through GPR32

Recovery of corneal sensitivity and increase in nerve density and wound healing in diabetic mice after PEDF plus DHA treatment

Defining a mechanistic link between pigment epithelium-derived factor, docosahexaenoic acid, and corneal nerve regeneration

Docosanoid signaling modulates corneal nerve regeneration: Effect on tear secretion, wound healing, and neuropathic pain

IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection

The anti-inflammatory potential of ACE2/angiotensin-(1-7)/Mas receptor axis: Evidence from basic and clinical research

HSV-1 and Zika virus but not SARS-CoV-2 replicate in the human cornea and are restricted by corneal type III interferon

Ocular surface impairment after COVID-19: A cohort study

SARS-CoV-2 on ocular surfaces in a cohort of patients with COVID-19 from the lombardy region

The Subread aligner: Fast, accurate and scalable read mapping by seed-and-vote

featureCounts: An efficient general purpose program for assigning sequence reads to genomic features

Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2

Enrichr: A comprehensive gene set enrichment analysis web server 2016 update

NetworkAnalyst 3.0: A visual analytics platform for comprehensive gene expression profiling and meta-analysis

Protein kinase C alpha and epsilon differentially modulate hepatocyte growth factorinduced epithelial proliferation and migration

The authors are grateful to Drs. Jovanny Zabaleta and Jone Garai (Louisiana Cancer Research Center Translational Genomics Core) for advice with RNA-seq library preparation and sequencing run. This work was supported by National Eye Institute Grants R21 EY031031 (H.E.P.B. and J.H.) and R01 EY019465 (to H.E.P.B.) and by an Institutional Grant from the School of Medicine, LSUHSC (to N.G.B.).

 Table 2 . Primers for qPCR.

Ace2 CAT TGG AGC AAG TGT TGG ATCTT GAG CTA ATG CAT GCC ATT CTCA   Cdkn2a  GGG GGC ACC AGA GGC AGT  GGT TGT GGC GGG GGC AGT T   Mmp1  GGG CTT GAA GCT GCT TAC GAATT CAG CAT CGA TAT GCT TCA CAG TTC T   Gapdh  TGG ACC TGA CCT GCC GTC TA  CCC TGT TGC TGT AGC CAA ATTC   Tfrc  GGC TAC TTG GGC TAT TGT AAAGG CAG TTT CTC CGA CAA CTT TCTCT   Hprt1  GAC CAG TCA ACA GGG GAC AT  AAC ACT TCG TGG GGT 

The authors declare no competing interests.